Evidence map›Paper›PMID 41576076›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

A fully synthetic Golden Gate assembly system for engineering a

Andrew P Sikkema, Kaitlyn E Kortright, Hemaa Selvakumar, Jyot Antani, Benjamin K Chan, Matthew Davidson, Max Hopkins, Benjamin Newman, Vladimir Potapov, Cecilia A Silva-Valenzuela and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. A fully synthetic Golden Gate assembly system for engineering aProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Andrew P Sikkema *Applied Molecular Biology Division, New England Biolabs Research Department, Ipswich, MA 01938.
Kaitlyn E Kortright *Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06511.
Hemaa SelvakumarFelix Biotechnology, San Francisco, CA 94080.
Jyot AntaniDepartment of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06511.ORCID 0000-0002-7402-983X
Benjamin K ChanDepartment of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06511.
Matthew DavidsonDepartment of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06511.ORCID 0009-0000-2945-6085
Max HopkinsFelix Biotechnology, San Francisco, CA 94080.
Benjamin NewmanApplied Molecular Biology Division, New England Biolabs Research Department, Ipswich, MA 01938.
Vladimir PotapovApplied Molecular Biology Division, New England Biolabs Research Department, Ipswich, MA 01938.ORCID 0000-0002-7690-3754
Cecilia A Silva-ValenzuelaApplied Molecular Biology Division, New England Biolabs Research Department, Ipswich, MA 01938.
S Kasra TabatabaeiApplied Molecular Biology Division, New England Biolabs Research Department, Ipswich, MA 01938.
Robert McBrideFelix Biotechnology, San Francisco, CA 94080.
Paul E TurnerDepartment of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06511.ORCID 0000-0003-3490-7498
Gregory J S LohmanApplied Molecular Biology Division, New England Biolabs Research Department, Ipswich, MA 01938.

Funding

Colton Center for Autoimmunity at Yale Pilot Award
6 · The paper itself

Abstract

Bacteriophages have applications in biotechnology, including human and veterinary medicine, agriculture, food safety, and biosecurity. One example of resurging importance is phage therapy, the use of phages to treat antibiotic-resistant bacterial infections. Phage therapy currently requires screening of environmental phages against the infecting strains for each individual patient, a laborious process that limits the development of standardized treatments. To overcome limitations of narrow host range inherent to many native phages, a robust genomic engineering platform is required which permits rapid and dependable genome production and engineering for nonmodel phage. Here, we describe an engineering platform for a phiKMV-like

Indexed as

Genetic EngineeringPseudomonas aeruginosaPseudomonas PhagesEscherichia coliGenome, Viralbacteriophagebiotechnologyphage therapyrecombinant geneticssynthetic biology

Identifiers

PMID41576076
PMCPMC12846835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.